Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Breast 1: Afatinib in HER2+ Metastatic Breast Cancer
NCT01125566Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2010
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 3, randomised, open-label trial of afatinib in HER2-positive breast cancer (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Progression-Free Survival at 34 months. Started Jun 2010; status: completed.
02
Drugs
afatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01125566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125566.